Xilio Therapeutics (XLO) Shares Outstanding (2020 - 2026)

Xilio Therapeutics (XLO) has 6 years of Shares Outstanding (Entity) data on file, last reported at $16.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Entity) rose 206.38% year-over-year to $16.3 million; the trailing twelve-month figure through Mar 2026 stood at $16.3 million (up 206.38% YoY), and the FY2025 full-year result was $8.4 million, up 155.76% from the prior year.
• Shares Outstanding (Entity) grew to $16.3 million in Q1 2026, from $8.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $16.3 million in Q1 2026 to a low of $2.0 million in Q1 2023.
• A 5-year average of $4.5 million and a median of $2.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) surged 390.01% in 2022 and retreated 0.0% in 2023, its largest moves.
• Tracing XLO's Shares Outstanding (Entity) over 5 years: stood at $2.0 million in 2022, then rose by 0.52% to $2.0 million in 2023, then jumped by 65.71% to $3.3 million in 2024, then jumped by 155.76% to $8.4 million in 2025, then jumped by 95.57% to $16.3 million in 2026.
• Business Quant data shows XLO's Shares Outstanding (Entity) at $16.3 million in Q1 2026, $8.4 million in Q4 2025, and $10.3 million in Q3 2025.